Best Life Sciences Platforms and Tools Companies in Minnesota, United States
The 44 best Life Sciences Platforms and Tools companies in Minnesota, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Recombinetics.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Minnesota
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Recombinetics Developer of gene repair and gene-editing technology to create animal models 35Moat top 19%Funding top 30%Patents top 32%Product top 36% All 10 signals ▾Moattop 19% Fundingtop 30% Patentstop 32% Producttop 36% Innovationtop 37% Globalbottom 42% Growthbottom 41% Techbottom 36% Marketbottom 33% Newsbottom 22% Moat: Editorial + unicorn rating 8/10 · IP moat: 242 patents Funding: Raised $66.8M across 25 rounds · 25 rounds over 15 yrs (1.7/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $67M | 16 mo ago | 29 29 → 17 (-41%) | — | WordPressMySQLPHP+17 | 241 patents Livestock genome editing and non‑meiotic allele introgression using pluripotent stem cells | — |
| 2 | Cytotheryx Developer of human hepatocytes for research and clinical applications 29Moat top 30%Patents top 37%Funding top 38%Innovation top 41% All 7 signals ▾Moattop 30% Patentstop 37% Fundingtop 38% Innovationtop 41% Talentbottom 49% Globalbottom 35% Marketbottom 25% Moat: IP moat: 14 patents · Soonicorn Patents: 14 patents matched (strict assignee match) · 14 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $60M | 7 mo ago | 12 | John Swart Chief Executive Officer | — | 14 patents Engineered human hepatocyte production, genetic modification, and biliary delivery platforms | — |
| 3 | Miromatrix Developing biologic human organs for transplantation | $52M | 62 mo ago | 77 | — | VimeoAzureCloudflare+10 | — | — |
| 4 | PamGene Provider of a microarray platform and gene expression profiling system for post-genomic applications | $18M | 38 mo ago | 38 | — | WordPressMySQLPHP+16 | — | 1 partnership |
| 5 | Calyxt Developer of bioreactor-based production system | $10M | 70 mo ago | 55 | — | — | 57 patents Plant-based delivery platforms for genome editing reagents and engineered plant cell matrices | — |
| 6 | Wilson Wolf Innovating cell and gene therapy manufacturing with G-Rex technology | $9M | 179 mo ago | 27 | John Wilson CEO | WordPressMySQLPHP+15 | 235 patents Closed, gas‑permeable bioreactor systems for scalable cell therapy manufacturing | — |
| 7 | Bio-Techne Developer of biotech reagents, instruments and clinical diagnostic products | $5M | 122 mo ago | 2,400 2,400 → 2,975 (+24%) | — | Apple iCloud MailMicrosoft 365Salesforce+24 | — | 1 internship · 1 partnership |
| 8 | Discovery Genomics Gene therapies for blood diseases | $4M | 186 mo ago | 6 | — | — | — | — |
| 9 | R&D Systems Developer of reagents and kits for biotech research and development | $2M | 96 mo ago | 788 | — | lit-htmllit-element | 1,296 patents High-resolution hydrogel inks and multi-plane stereolithography for advanced 3D printing | 3 launchs |
| 10 | RoverMed Biosciences Developer of nanocapsules for cancer treatment | $2M | 102 mo ago | 3 | — | — | — | — |
| 11 | ImmunoChemistry Immunoassay solutions: cell viability assays, ELISA & IHC reagents, custom services | $2M | 203 mo ago | 6 | — | — | 7 patents In vivo apoptosis imaging agents for diagnostic and therapeutic monitoring | — |
| 12 | GeneSegues Therapeutics Developer of RNAi-based targeted drugs for the treatment of cancer | $2M | 161 mo ago | — | Gretchen Unger Founder | — | — | — |
| 13 | ZirChrom Separations Innovating zirconia and titania-based HPLC stationary phases and columns | $2M | 300 mo ago | — | Clayton McNeff CEO | — | — | — |
| 14 | Medisyn Tech Medisyn Technologies is a unique bioactive compound design and discovery company focused on novel… | $2M | 258 mo ago | 4 | — | — | — | — |
| 15 | Photonic Pharma Pioneering precision in early-phase drug discovery with advanced biosensor technology | $1M | 52 mo ago | 11 | Jennifer Thomas Co-Founder | — | — | — |
| 16 | Stratix Labs Developer of products for research, development, and quality control applications in microbiology workflows | $1M | 53 mo ago | 7 | Joshua Erickson Founder | — | 16 patents Microbial inoculation devices and UV disinfection efficacy testing systems | — |
| 17 | BRTI Life Sciences Biomimetic tools for 3D cell culture | $1M | 148 mo ago | 13 | — | — | — | — |
| 18 | Geneticure Personalized hypertension treatment through DNA analysis for better medication selection | $1M | 112 mo ago | 9 | — | — | 19 patents Genetic diagnostics and therapeutics for hypertension and coronavirus infections | — |
| 19 | B-MoGen Developer of solutions for gene editing and gene delivery | $1M | 96 mo ago | 20 | — | — | — | — |
| 20 | Mill Creek Life Sciences Accelerating cell-based therapies with innovative human platelet lysate solutions | $725K | 132 mo ago | 6 | — | Cart FunctionalityWordPressMySQL+22 | — | — |
| 21 | Attostar Provides molecular and microbial detection reagents | $402K | 51 mo ago | — | Steve Marker CEO & President | — | — | — |
| 22 | FemtoFluidics Developer of microfluidics technology for drug discovery | $275K | 19 mo ago | — | Zachary Xiong Co-Founder | — | 2 patents Digital microfluidic platforms for combinatorial chemical library synthesis | — |
| 23 | MNPHARM Manufacturer of recombinant proteins using plant-based molecular farming for research | $150K | 38 mo ago | 4 | Jeff Reinert Co-Founder & President | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Minnesota
#1
Series A · Rochester, Minnesota · founded 2018 · 12 employees$60Mraised▾
Developer of human hepatocytes (HHC) for research and clinical applications. The company develops HHC for toxicology study, hepatitis research, and allotransplants.
- Jan 2026Conventional Debt—
- Jan 2026Series A$60M
#2
Series A · New Brighton, Minnesota · founded 2008 · 29 employees$66.8Mraised▾
Developer of gene repair and gene-editing technology to create animal models. it uses its technologies in the agricultural arena to accelerate the breeding of natural characteristics into pigs and other livestock to enhance their health and welfare, and advance food production and safety. Recombinetics, in the biomedical arena, also applies its genome editing solutions and TALEN technologies to create viable large animal models for human disease research as part of the development of therapeutic compounds, medical devices, and protocols.
- Apr 2025Grant (prize money)$297.9K
- Mar 2025Grant (prize money)$297.9K
- 2024Grant (prize money)$385K
- 2023Grant (prize money)$342.2K
#3
Series B · Virginia, Minnesota · founded 1999 · 38 employees$17.9Mraised▾
PamGene, is a biomarker company focused on developing a microarray platform and gene expression profiling system for post-genomic applications. It has a proprietary array-based platform to measure the activities of kinases & nuclear receptors so as to understand the drug interactions of these signaling molecules. The patented technology has a wide range of applications for research, biomarker, and toxicology groups in lead identification and optimization, pre-clinical/clinical & translational research, and biomarker development.
- Jun 2023Grant (prize money)$8.2M
- Jan 2019Grant (prize money)$456.1K
- Dec 2017Grant (prize money)$303.8K
- Jan 2016Grant (prize money)$510K
#4
Acquired · Eden Prairie, Minnesota · founded 2009 · 77 employees$51.5Mraised▾
Miromatrix Medical is developing fully biological replacement organs for the human body. Its first product is a bio mesh for hernia repair and breast reconstruction and is also trying to create human organs including the liver, lung, kidney, pancreas, and heart. The mesh is a non-cross-linked, acellular surgical mesh that is derived from the highly vascularized porcine liver. The products involve the use of technologies like the perfusion decellularization process that involves the removal of all cellular components by passing a mild detergent through the native vascular system of a biological structure (organ, bone, or tissue), this allows the generation of a scaffold or biological matrix.
- May 2021Series C—
- Oct 2019Grant (prize money)$2M
- Sep 2019Grant (prize money)$1.7M
- Jul 2018Series B$15.7M
#5
Funding Raised · Saint Paul, Minnesota · founded 2022$274.9Kraised▾
Developer of microfluidics technology for drug discovery. It offer AI-based platform to replace traditional liquid-handling robotics with electronic technology. that can synthesize and manipulate small volumes of liquid for the development of new drugs and therapies.
- Jan 2025Grant (prize money)$274.9K
#6
Deadpooled · Roseville, Minnesota · founded 2010 · 55 employees$10Mraised▾
Developer of a bioreactor-based production system. It levarages a technology platform to deliver innovative materials and products includingBioFactory a bioreactor-based production system that enables the controlled replication and processing of plant-based molecules producing compounds using a matrix of plant cells.
- Oct 2020Post IPO$10M
#7
Funding Raised · Saint Paul, Minnesota · founded 1998 · 27 employees$8.8Mraised▾
Innovating cell and gene therapy manufacturing with G-Rex technology. They are dedicated to creating hope for cancer patients through innovative cell culture devices. Their G-Rex platform cost-effectively manufactures life-saving drug products. They strive to advance cell and gene therapy by expanding knowledge and adapting the G-Rex platform for economical and scalable drug product manufacturing. They pioneer the development of innovative mammalian cell culture devices for applications including monoclonal antibody production, living skin, corneal storage, porcine heart valve testing, islet transplants, and cell and gene therapy. They unite stakeholders for the greater good, providing the foundation for a practical and cost-effective way to make cell and gene therapy drug products. Their G-Rex centric platform is versatile and scalable for R&D to commercial drug product manufacturing.
- Sep 2011Grant (prize money)$1.2M
- Sep 2010Grant (prize money)$113.5K
- Apr 2010Grant (prize money)$3.8M
- Apr 2008Grant (prize money)$3.8M
#8
Public · Minneapolis, Minnesota · founded 1981 · 2400 employees$5.3Mraised▾
Developer of biotech reagents, instruments, and clinical diagnostic products. It is engaged in providing specialized proteins, including cytokines and growth factors, antibodies, related immunoassays, biologically active small molecules, and other reagents to the research, diagnostics, and clinical control markets. The Company also supports its customers with instrumentation designed to simplify key protein analysis processes.
- Jun 2016Grant (prize money)$153K
- Mar 2016Grant (prize money)$225K
- Aug 2014Grant (prize money)$202.1K
- Mar 2012Grant (prize money)$216.9K
#9
Acquired · Saint Paul, Minnesota · founded 2015 · 7 employees$1.4Mraised▾
Developer of products for research, development, and quality control applications in microbiology workflows. The company has the product Instant Inoculator that helps in growth promotion testing and other QC microbiology testing. Another product ReadyNowTest Carriers are pre-inoculated and used for disinfectant and sanitizer efficiency testing.
- Mar 2022Seed$500K
- Apr 2021Seed$786.4K
- Jan 2020Seed$50K
- Apr 2019Seed$60K
#10
Funding Raised · Minneapolis, Minnesota · founded 2014 · 11 employees$1.4Mraised▾
Pioneering precision in early-phase drug discovery with advanced biosensor technology. The company focuses on lead discovery, utilizing a technology platform combining fluorescent biosensor engineering and fluorescence lifetime detection in living cells. This approach dramatically increases the precision of high-throughput screening of small-molecule libraries, potentially transforming pharmaceutical development productivity. They partner with industrial and academic collaborators, applying proprietary advancements in structure-based drug-screening technology to discover novel small-molecule effectors of therapeutically important protein targets. The company has assembled a robust network of techniques, concepts, facilities, and collaborators to address a wide range of therapeutic goals. Their expertise lies in engineering fluorescent protein biosensors, innovative high-throughput screening technology, and secondary functional assays, producing a strategy for lead discovery with unprecedented speed and efficiency. This involves genetic engineering, fluorescence resonance energy transfer (FRET), and medicinal chemistry, all contributing to advancements in drug discovery.
- Apr 2022Grant (prize money)$306.5K
- Jan 2021Grant (prize money)$499.4K
- Sep 2019Grant (prize money)$593.9K
#11
Acquired · Minneapolis, Minnesota · founded 2000 · 6 employees$4Mraised▾
Discovery Genomics, a functional genomics company created to discover gene functions, conduct drug target validations, and design therapeutic agents based on genomics information. The company holds exclusive licenses from the University of Minnesota to develop technologies related to "knock-downs" in Zebrafish using a proprietary Morphant(TM) technology and to the use of the Sleeping Beauty Transposon(TM). Both technologies may be used for functional genomics and the discovery of drug targets. The transposon may have applications in gene therapy. Morphant(TM) "knock-downs" are used to suppress and thereby study the functions of particular genes.
- Feb 2011Grant (prize money)$1.8M
- Mar 2010Grant (prize money)$270.7K
- Aug 2001Series A$4M
#12
Funding Raised · Minneapolis, Minnesota · founded 1985 · 788 employees$2.4Mraised▾
Developer of reagents and kits for biotech research and development. The company's range of products includes natural and recombinant proteins, antibodies, ELISAs, Luminex and other high-performance assays, stem cell products, cell culture, small molecules and peptides, ELISpot assays, cDNA clones, flow cytometry workflow solutions and antibody arrays.
- Aug 2018Grant (prize money)$1.6M
- Apr 2004Grant (prize money)$813.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Minnesota is moving
A read on the academic research around Bioinformatics in Minnesota — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 114 papers.
- University of Minnesota86
- University of Minnesota Medical Center24
- University of Minnesota System16
- Minnesota Department of Health5
- University of Minnesota Rochester3
- Gene2→9
- Genome editing2→3
- Biomarker3
- Immune system3
- Population3
- Transcriptome3
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2
- Disease4
- Immune system3
- Microbiome3
- Gut microbiome3
- Cognition2
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.